Michael Jeffrey Abrams

Protiva Biotherapeutics, Inc. develops pharmaceutical products for human diseases. The firm offers drugs for cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. The company was founded in September, 2000 and is headquartered in Seattle, WA.

MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada.

Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^

Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada.

Inimex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of Innate Defense Regulators (IDRs). IDRs are novel drugs that selectively trigger the body's innate defenses, protecting against antibiotic-resistant infections and controlling inflammation. The company was founded in 2001 and is headquartered in Vancouver, Canada.

AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases.